Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
暂无分享,去创建一个
J. Mascola | R. Wyatt | C. Bewley | G. Shaw | M. Roederer | Z. Sheng | T. Zhou | L. Shapiro | P. Kwong | S. O'dell | Hui Li | J. Gorman | H. Welles | R. Mason | Sabrina Lusvarghi | Cameron Adams | B. Chakrabarti | Richard Nguyen | S. O’dell | Zizhang Sheng
[1] E. Hunter,et al. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses , 2015, Proceedings of the National Academy of Sciences.
[2] H. Schuitemaker,et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys , 2015, Science.
[3] G. Nabel,et al. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014. , 2015, Vaccine.
[4] B. Pulendran,et al. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope , 2015, Journal of Virology.
[5] John R Mascola,et al. Antibody responses to envelope glycoproteins in HIV-1 infection , 2015, Nature Immunology.
[6] L. Morris,et al. HIV broadly neutralizing antibody targets , 2015, Current opinion in HIV and AIDS.
[7] T. Kepler,et al. Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization , 2015, Nature Communications.
[8] Gwo-Yu Chuang,et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.
[9] Y. Guan,et al. Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1 , 2014, Front. Immunol..
[10] James C Paulson,et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.
[11] G. Alter,et al. Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies , 2014, PloS one.
[12] Han Gao,et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.
[13] Gary J. Nabel,et al. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.
[14] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[15] David Baker,et al. Proof of principle for epitope-focused vaccine design , 2014, Nature.
[16] Richard Wilson,et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign , 2014, Proceedings of the National Academy of Sciences.
[17] Mario Roederer,et al. Immunological and Virological Mechanisms of Vaccine-Mediated Protection Against SIV and HIV , 2013, Nature.
[18] L. Stamatatos,et al. Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D , 2013, Journal of Virology.
[19] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[20] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[21] Jerome H. Kim,et al. Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.
[22] John P. Moore,et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation , 2013, Proceedings of the National Academy of Sciences.
[23] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[24] J. Mascola,et al. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.
[25] Youdong Mao,et al. A Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization , 2013, PloS one.
[26] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[27] B. Haynes,et al. Progress in HIV-1 vaccine development , 2013, Current opinion in HIV and AIDS.
[28] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[29] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[30] G. Learn,et al. Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock , 2013, Journal of Virology.
[31] L. Morris,et al. Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies , 2013, Journal of Virology.
[32] H. Robinson. Non-neutralizing antibodies in prevention of HIV infection , 2013, Expert opinion on biological therapy.
[33] L. Stamatatos,et al. Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS pathogens.
[34] S. Self,et al. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. , 2012, Journal of immunological methods.
[35] Ron Diskin,et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.
[36] Bin Li,et al. Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. , 2012, Virology.
[37] J. Mascola,et al. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.
[38] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[39] M. Hassall,et al. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model , 2012, Retrovirology.
[40] J. Mascola,et al. Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys , 2012, Journal of Virology.
[41] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[42] Young Do Kwon,et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops , 2012, Proceedings of the National Academy of Sciences.
[43] B. Korber,et al. Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages , 2012, Journal of Virology.
[44] Jerome H. Kim,et al. Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.
[45] John P. Moore,et al. SHIV-162P3 Infection of Rhesus Macaques Given Maraviroc Gel Vaginally Does Not Involve Resistant Viruses , 2011, PloS one.
[46] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[47] S. Rowland-Jones,et al. Potent Autologous and Heterologous Neutralizing Antibody Responses Occur in HIV-2 Infection across a Broad Range of Infection Outcomes , 2011, Journal of Virology.
[48] F. Månsson,et al. Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1 , 2011, Journal of Virology.
[49] G. Gottlieb,et al. Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection , 2011, Journal of Virology.
[50] T. Kepler,et al. Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.
[51] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[52] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[53] Jamie K. Scott,et al. Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies , 2011, Journal of Virology.
[54] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[55] Barney S. Graham,et al. Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.
[56] John P. Moore,et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody , 2011, Proceedings of the National Academy of Sciences.
[57] R. Wyatt,et al. Direct Antibody Access to the HIV-1 Membrane-Proximal External Region Positively Correlates with Neutralization Sensitivity , 2011, Journal of Virology.
[58] Véronique Giudicelli,et al. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. , 2011, Cold Spring Harbor protocols.
[59] M. Hudgens,et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys , 2011, Science Translational Medicine.
[60] J. Kappes,et al. An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum , 2011, Journal of Virology.
[61] D. Montefiori,et al. Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen , 2011, Journal of Virology.
[62] D. Venzon,et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. , 2011, Vaccine.
[63] Jamie K. Scott,et al. Comparison of Antibody Repertoires Produced by HIV-1 Infection, Other Chronic and Acute Infections, and Systemic Autoimmune Disease , 2011, PloS one.
[64] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[65] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[66] C. Andrews,et al. Genetic immunization in the lung induces potent local and systemic immune responses , 2010, Proceedings of the National Academy of Sciences.
[67] T. Miura,et al. Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display. , 2010, AIDS research and human retroviruses.
[68] R. Desrosiers,et al. Diversity of envelope genes from an uncloned stock of SIVmac251. , 2010, AIDS research and human retroviruses.
[69] N. Haigwood,et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques , 2010, Nature Medicine.
[70] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[71] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[72] Dennis R. Burton,et al. Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16 , 2010, Journal of Virology.
[73] R. Koup,et al. Amine‐Reactive Dyes for Dead Cell Discrimination in Fixed Samples , 2010, Current protocols in cytometry.
[74] B. Korber,et al. Autologous Neutralizing Antibodies to the Transmitted/Founder Viruses Emerge Late after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys , 2010, Journal of Virology.
[75] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[76] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[77] Tongqing Zhou,et al. Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.
[78] A. Perelson,et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.
[79] D. Burton,et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.
[80] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[81] J. Sodroski,et al. Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State , 2009, PLoS pathogens.
[82] K. Abel,et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study , 2009, Human vaccines.
[83] B. Korber,et al. Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate , 2009, Journal of Virology.
[84] J. Heeney,et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. , 2008, Virology.
[85] Marie-Paule Lefranc,et al. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis , 2008, Nucleic Acids Res..
[86] R. Gallo,et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens , 2007, Proceedings of the National Academy of Sciences.
[87] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[88] J. Mascola,et al. A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates , 2005, Journal of Virology.
[89] R. Wyatt,et al. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. , 2005, Virology.
[90] J. Sodroski,et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[91] D. Burton,et al. Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities , 2003, Journal of Virology.
[92] J. Sodroski,et al. Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.
[93] Gianni Cesareni,et al. Unusual Binding Properties of the SH3 Domain of the Yeast Actin-binding Protein Abp1 , 2002, The Journal of Biological Chemistry.
[94] J. Robinson,et al. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. , 2001, Virology.
[95] M. Malim,et al. Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4 , 2001, Journal of Virology.
[96] C. Bewley,et al. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. , 2001, Journal of the American Chemical Society.
[97] R. Doms,et al. Characterization and Epitope Mapping of Neutralizing Monoclonal Antibodies Produced by Immunization with Oligomeric Simian Immunodeficiency Virus Envelope Protein , 2000, Journal of Virology.
[98] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[99] Q. Sattentau,et al. Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120 , 1999, Journal of Virology.
[100] D. Montefiori,et al. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. , 1998, AIDS research and human retroviruses.
[101] J. Robinson,et al. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. , 1998, AIDS research and human retroviruses.
[102] L. Pannell,et al. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. , 1998, Protein expression and purification.
[103] D. Dormont,et al. Production and characterization of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1997, AIDS research and human retroviruses.
[104] L K Pannell,et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.
[105] D. Montefiori,et al. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. , 1996, Virology.
[106] K. Kent. Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein , 1995, Journal of medical primatology.
[107] R. Desrosiers,et al. Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity , 1994, Journal of virology.
[108] E. Rud,et al. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. , 1992, AIDS research and human retroviruses.
[109] L. Gritz,et al. Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.
[110] R. Garlick,et al. Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. , 1990, AIDS research and human retroviruses.
[111] L. Morris,et al. The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.
[112] J. Sodroski,et al. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. , 1992, Journal of acquired immune deficiency syndromes.